GoodGut
Focused on researching and developing analysis systems and therapeutic products to improve the diagnosis and treatment of digestive diseases based on intestinal microbiota.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
N/A | Support Program | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 241 % | (33 %) | 441 % | (48 %) | 36 % | 518 % | 15 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (262 %) | (686 %) | (83 %) | (487 %) | (748 %) | (208 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 136 % | 116 % | 68 % | (926 %) | (1142 %) | (238 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
GoodGut is a biotechnology company specializing in the development of diagnostic solutions for colorectal cancer and gastrointestinal disorders. The company operates in the healthcare and biotechnology market, focusing on creating non-invasive tests that utilize fecal bacterial markers to improve the accuracy of disease detection. GoodGut serves healthcare providers, laboratories, and patients by offering advanced diagnostic tools that reduce false positive rates and enhance early detection. The business model is centered around the research, development, and commercialization of proprietary diagnostic tests and supplements. Revenue is generated through the sale of diagnostic kits, licensing agreements, and partnerships with healthcare institutions.
Keywords: biotechnology, diagnostics, colorectal cancer, gastrointestinal disorders, fecal bacterial markers, non-invasive tests, healthcare, early detection, proprietary tests, supplements.